Patent · US Active

Dosing regimen for treating inflammatory bowel disease

US12304956B1 · kind B1 · utility

1Cited by
69References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 16, 2024
Grant dateMay 20, 2025
Priority date
Expiry dateJul 16, 2044

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/94
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are variant α4β7 integrin antibodies and methods of use.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.